and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

Claim 51. (Amended) A pharmaceutically acceptable salt of claim 70 selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

Claim 52. (Amended) A pharmaceutically acceptable salt of claim 71 selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

Claim 53. (Amended) A pharmaceutically acceptable salt of claim 72 selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

Claim 54. (Amended) A pharmaceutically acceptable salt of claim 73 selected from the group consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

Please add new claims 68-109 as follows.

--68. A pharmaceutically acceptable salt of a compound selected from the group consisting of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N*=-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*=-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea and their pharmaceutically acceptable salts.

69. A pharmaceutically acceptable salt of the compound *N*-(5-*tert*-butyl-2-methoxy phenyl)-*N*=-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea.

70. A pharmaceutically acceptable salt of the compound *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

71. A pharmaceutically acceptable salt of the compound *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

72. A pharmaceutically acceptable salt of the compound *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

73. A pharmaceutically acceptable salt of the compound *N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*=-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

74. A method for the treatment of a cancerous cell growth mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of a compound selected from the group consisting of:
N-(5-*tert*-butyl-2-methoxy phenyl)-*N*=-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*=-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

75. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of *N*-(5-tert-butyl-2-methoxy phenyl)-*N*=-(4-(4-methoxy-3-(*N*-methyl carbamoyl)phenoxy)phenyl) urea.

76. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of *N*-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

77. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

78. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

79. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering a pharmaceutically acceptable salt of *N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*=-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

80. A method as in claim 74 for the treatment of solid cancers.

81. A method as in claim 74 for the treatment of carcinomas, myleoid disorders or adenomas.

82. A method as in claim 75 for the treatment of carcinomas, myleoid disorders or adenomas.

83. A method as in claim 76 for the treatment of carcinomas, myleoid disorders or adenomas.

84. A method as in claim 77 for the treatment of carcinomas, myleoid disorders or adenomas.

85. A method as in claim 78 for the treatment of carcinomas, myleoid disorders or adenomas.

86. A method as in claim 79 for the treatment of carcinomas, myleoid disorders or adenomas.

87. A method as in claim 74 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

88. A method as in claim 75 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

89. A method as in claim 76 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

90. A method as in claim 77 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

91. A method as in claim 78 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

92. A method as in claim 79 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

93. A method as in claim 74 for the treatment of myeloid leukemia or villous colon adenomas.

94. A method as in claim 75 for the treatment of myeloid leukemia or villous colon adenomas.

95. A method as in claim 76 for the treatment of myeloid leukemia or villous colon adenomas.

96. A method as in claim 77 for the treatment of myeloid leukemia or villous colon adenomas.

97. A method as in claim 78 for the treatment of myeloid leukemia or villous colon adenomas.

98. A method as in claim 79 for the treatment of myeloid leukemia or villous colon adenomas.

99. A method as in claim 74 wherein the pharmaceutically acceptable salt administered is selected from the group of salts consisting of

a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and

b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

100. A method as in claim 75 where the pharmaceutical acceptable salt administered is the tosylate salt of
N-(5-tert-butyl-2-methoxy phenyl)-*N*=-(4-(4-methoxy-3-(*N*-methyl carbamoyl)phenoxy)phenyl) urea.

101. A method as in claim 76 where the pharmaceutical acceptable salt administered is the tosylate salt of
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

102. A method as in claim 77 where the pharmaceutical acceptable salt administered is the tosylate salt of
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

103. A method as in claim 78 where the pharmaceutical acceptable salt administered is the tosylate salt of
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

104. A method as in claim 79 where the pharmaceutical acceptable salt administered is the tosylate salt of
N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*=-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

105. A pharmaceutical acceptable salt as in claim 69 which is the tosylate salt of
N-(5-*tert*-butyl-2-methoxy phenyl)-*N*=-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea.

106. A pharmaceutical acceptable salt as in claim 70 which is the tosylate salt of
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

107. A pharmaceutical acceptable salt as in claim 71 which is the tosylate salt of *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

108. A pharmaceutical acceptable salt as in claim 72 which is the tosylate salt of *N*-(4-chloro-3-(trifluoromethyl)phenyl)-*N*=-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

109. A pharmaceutical acceptable salt as in claim 73 which is the tosylate salt of *N*-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N*=-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.--